Molecular Partners AG Comments on Allergan Inc.'s Progress in Phase IIa Retinal Disease Trial Using Anti-VEGF DARPin®
ZURICH-SCHLIEREN, Switzerland--(BUSINESS WIRE)--Molecular Partners AG today commented on the recent progress with its anti-VEGF DARPin (AGN-150998/MP0112), which is being developed in partnership with Allergan for ocular indications. Allergan announced last week at their R&D day that the compound successfully completed phase IIa development. AGN-150998/MP0112 was shown to be safe and well tolerated, with no dose limiting toxicity, after a single administration. Further, preliminary efficacy results from this study suggest a dosing interval of up to 3 months. Based on these results, Allergan has initiated a double-masked Phase IIb study comparing two high doses of AGN-150998/MP0112 with Lucentis, the current standard of care.